Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R21 Clinical Trial Not Allowed)
Research grant to study new risk factors for liver cancer susceptibility in the US, considering biological, environmental, and social factors, alongside established risks like viral hepatitis.
This grant is no longer accepting proposals
National Institutes of Health has archived this opportunity.
Funder: National Institutes of Health
Due Dates: February 16, 2025 (New) | March 16, 2025 (Renewal/Resubmission/Revision) | May 8, 2025 (Expiration)
Funding Amounts: Up to $275,000 direct costs over 2 years; no more than $200,000 in any single year; project period max 2 years.
Summary: Supports innovative epidemiologic research on emerging biological, environmental, and social risk factors for liver cancer susceptibility in the U.S., beyond established risks like viral hepatitis.
Key Information: Clinical trials are not allowed; applications focused solely on viral hepatitis or cohort infrastructure are non-responsive.
Description
This NIH funding opportunity supports exploratory/developmental (R21) epidemiologic research to identify and understand novel and emerging risk factors for liver cancer (including hepatocellular carcinoma and other subtypes) in the United States. The program encourages studies that investigate the interplay of new biological, environmental, and social risk factors with established risks (such as viral hepatitis), aiming to inform evidence-based prevention and control strategies. Research may include, but is not limited to, the roles of metabolic syndrome, obesity, diabetes, non-alcoholic fatty liver disease (NAFLD), environmental exposures, and social determinants in liver cancer etiology and progression.
